Valuation: Cardiol Therapeutics Inc.

Market Cap 24Cr 18Cr 15Cr 14Cr 13Cr 1.67TCr 25Cr 167.61Cr 66Cr 838.42Cr 66Cr 64Cr 2.8TCr P/E 2026 *
-4.42x
P/E 2027 * -9.12x
Enterprise Value 23Cr 16Cr 14Cr 13Cr 12Cr 1.57TCr 23Cr 157.32Cr 61Cr 786.93Cr 62Cr 61Cr 2.62TCr EV / Sales 2026 *
-
EV / Sales 2027 * 70.5x
Free-Float
97.63%
Yield 2026 *
-
Yield 2027 * -
13/08 Cardiol Therapeutics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 CI
12/05 Cardiol Therapeutics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026 CI
07/05 Cardiol Adds Results "Further Validate" Ongoing Phase III Trial, Which Recently Surpassed 75% Enrollment MT
07/05 Cardiol Says Results Demonstrate CardiolRx "May Represent a Paradigm Shift" In the Treatment of Patients With Recurrent Pericarditis MT
07/05 Cardiol Therapeutics Says Its Phase II MAvERIC Results Accepted For Publication In The Journal Of The American Heart Association MT
07/05 Cardiol Therapeutics Inc Announces Phase II Maveric Results Accepted for Publication in the Journal of the American Heart Association CI
28/04 Cardiol Therapeutics Up In US Premarket As Expands Phase 3 Maveric Trial to Include 7 More Clinical Centers in the U.S. MT
28/04 Cardiol Therapeutics Inc. Expands Maveric Phase III Trial Network and Provides Clinical Updates on Cardiolrx CI
01/04 Cardiol Therapeutics Fiscal 2025 Loss Narrows; Says Now Fully Funded Through Completion of MAVERIC trial MT
01/04 Cardiol Therapeutics initiated pivotal Phase III Maveric trial of Cardiolrx in recurrent pericarditis RE
01/04 Cardiol Therapeutics Inc. Provides Update on Strategic Priorities CI
01/04 Cardiol Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 CI
10/02 Cardiol Therapeutics Inc. Announces the Publication of Results from Its Phase II Archer Study in ESC Heart Failure CI
1 day+7.55%
1 week+18.13%
Current month+29.55%
1 month+52.00%
3 months+21.93%
6 months+62.86%
Current year+74.05%
1 week 1.89
Extreme 1.89
2.28
1 month 1.5
Extreme 1.5
2.28
Current year 1.22
Extreme 1.225
2.33
1 year 1.22
Extreme 1.225
2.33
3 years 0.91
Extreme 0.91
4.26
5 years 0.61
Extreme 0.61
6.19
10 years 0.61
Extreme 0.61
8.49
Manager TitleAgeSince
Chief Executive Officer - 19/01/2017
Director of Finance/CFO - 16/08/2018
Chief Operating Officer - 03/12/2020
Director TitleAgeSince
Director/Board Member - 15/12/2017
Director/Board Member - 19/01/2017
Chairman - 07/07/2021
Date Insider Type Main position Quantity % Market Cap.
30/06/26 Option

Director

30,000 0.0260%
30/06/26 Option

Chairman

45,238 0.0392%
30/06/26 Option

Director

30,000 0.0260%
Change 5-day change 1-year change 3-year change Capi.($)
+7.55%+18.13%+49.02%+83.87% 18Cr
+1.34%+1.24%+4.18%+16.07% 4.87TCr
-0.14%+4.17%+471.28%+586.87% 4.4TCr
-0.44%+8.67%+16.55%+75.58% 4.08TCr
+0.13%+3.59%+26.57%+9.39% 3.98TCr
-4.04%+6.15%+23.03%+48.00% 3.27TCr
-1.02%+1.45%+26.82%+123.44% 1.67TCr
-3.29%-0.80% - - 1.68TCr
+0.57%+0.17%+4.79%+21.40% 1.39TCr
-0.55%+6.74%+82.84%+30.66% 1.36TCr
Average +0.01%+4.72%+78.34%+110.58% 2.67TCr
Weighted average by Cap. -0.60%+3.94%+100.13%+137.46%

Financials

2026 *2027 *
Net sales - 33.21L 23.86L 20.67L 19.37L 17.66L 23Cr 33.72L 2.28Cr 89.04L 11Cr 89.58L 87.63L 38Cr
Net income -3.52Cr -2.53Cr -2.19Cr -2.05Cr -1.87Cr -241.24Cr -3.57Cr -24Cr -9.44Cr -120.79Cr -9.5Cr -9.29Cr -402.79Cr -3.06Cr -2.2Cr -1.9Cr -1.78Cr -1.63Cr -209.48Cr -3.1Cr -21Cr -8.2Cr -104.89Cr -8.25Cr -8.07Cr -349.75Cr
Net Debt -1.5Cr -1.08Cr -93.4L -87.52L -79.82L -102.83Cr -1.52Cr -10Cr -4.02Cr -51Cr -4.05Cr -3.96Cr -171.68Cr -1.03Cr -73.67L -63.83L -59.8L -54.55L -70Cr -1.04Cr -7.03Cr -2.75Cr -35Cr -2.77Cr -2.71Cr -117.32Cr
Logo Cardiol Therapeutics Inc.
Cardiol Therapeutics Inc. is a Canada-based clinical-stage life sciences company focused on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small-molecule drug candidate, CardiolRx (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It holds investigational new drug application authorization from the United States Food and Drug Administration (US FDA) to conduct clinical studies to evaluate the efficacy and safety of CardiolRx in two diseases affecting the heart: recurrent pericarditis and acute myocarditis. The MAVERIC Program in recurrent pericarditis, an inflammatory disease, comprises the completed Phase II MAvERIC-Pilot study (NCT05494788) and the ongoing Phase III MAVERIC trial (NCT06708299). The Company is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure.
Employees
18
Date Price Change Volume
13/26/13 CA$2.280 +7.55% 27,132
12/26/12 CA$2.120 +0.47% 2,36,815
11/26/11 CA$2.110 +2.43% 1,51,752
10/26/10 CA$2.060 +3.52% 2,64,754
07/26/07 CA$1.990 +3.11% 1,27,972
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.120CAD
Average target price
6.000CAD
Spread / Average Target
+183.02%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CRDL Stock